World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
73
Citations
44290
World Ranking
2079
National Ranking
1016

John R. Wunderlich publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where John R. Wunderlich sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 148 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

John R. Wunderlich D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where John R. Wunderlich sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

John R. Wunderlich is affiliated with the National Institutes of Health in the United States. Their research focuses primarily on medicine, with particular emphasis on immunology and microbiology.

Their subfields of study include oncology and immunology, reflecting a concentrated interest in cancer and immune system functions. The main topics covered in their work encompass immunotherapy and immune responses, CAR-T cell therapy research, and cancer immunotherapy and biomarkers.

Wunderlich's research outputs are published in venues such as Cancer Research. A notable publication from 2021 is titled "Abstract 1509: A signature for tumor neoantigen-reactive T-cells in fresh human lung cancers allows rapid cloning of their receptors," published in Cancer Research.

  • Ken-ichi Hanada
  • Chihao Zhao
  • Raúl Gil-Hoyos
  • Jared J. Gartner
  • Christopher A. Chow

This list represents frequent co-authors who have collaborated on related research projects, contributing to the collective body of scientific work in cancer immunotherapy and cellular therapies.

  • Cancer Research

Best Publications

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  • Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

    Mojgan Ahmadzadeh;Laura A. Johnson;Bianca Heemskerk;John R. Wunderlich

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

    Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  • Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

    Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  • A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

    Michael H. Kershaw;Michael H. Kershaw;Michael H. Kershaw;Jennifer A. Westwood;Jennifer A. Westwood;Linda L. Parker;Gang Wang;Gang Wang

  • PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

    Alena Gros;Paul F. Robbins;Xin Yao;Yong F. Li

  • Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients

    Mark E. Dudley;John R. Wunderlich;Thomas E. Shelton;Jos Even

  • Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

    Alena Gros;Maria R Parkhurst;Eric Tran;Anna Pasetto

  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

    Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  • Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

    Sanja Stevanović;Lindsey M. Draper;Michelle M. Langhan;Tracy E. Campbell

  • Immunogenicity of somatic mutations in human gastrointestinal cancers

    Eric Tran;Mojgan Ahmadzadeh;Yong Chen Lu;Alena Gros

  • Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy

    Paul F. Robbins;Mark E. Dudley;John Wunderlich;Mona El-Gamil

  • Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

    Mark E. Dudley;John Wunderlich;Michael I. Nishimura;David Yu

  • A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Patrick Hwu

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Paul F. Robbins
Paul F. Robbins National Cancer Institute
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
David M. Segal
David M. Segal University of California, Davis
Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career opportunities. Many professionals transition into nursing fields, where a strong background in immunology is invaluable. Options like accelerated FNP programs provide a fast track to becoming a Family Nurse Practitioner, combining clinical expertise with immunological knowledge. You can find reputable options by researching accelerated fnp program offerings.

Non-nurses seeking entry into nursing may consider online rn programs for non nurses. These programs are designed to equip learners with foundational nursing skills quickly while allowing flexibility in completing the curriculum remotely.

If speed and accessibility are priorities, many students look for accelerated nursing programs near me. These programs focus on fast-paced coursework that can help qualified individuals earn a Bachelor of Science in Nursing (BSN) efficiently.

For careers with shorter training periods, easiest lpn programs to get into can be a practical starting point. Licensed Practical Nurse (LPN) programs offer hands-on training and strong employment prospects, often serving as a stepping stone to further advanced nursing degrees.

Best Scientists Citing John R. Wunderlich

Trending Scientists

Recently Published Articles